Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Sigmund who wrote (720)	12/18/1997 2:44:00 PM
From: Frank Buck	Respond to of 1894

Sigmund, I agree on all counts. I like your ability to look beyond tomorrow, and what we can expect to see happen with a company's stock, based on how it benefits society. What is wrong with that? Absolutely nothing! Capitalism has shown to be the greatest overall-benefit to mankind since we became bi-pedal. Let the markets determine the new entrants based on ease of entry. Investors will evaluate their merits. The smart/adept/intuitive companies will always be flexible and hear or read what the newest level of technology is required to benefit the masses. Those who don't will go the way of the T-Rex. Good riddance to them. A tree that bends with the wind lasts the longest. Must be philosophy hour or my blood-sugar is getting low. <g> Your perception shows a level of insight that is often lacking in most shareholders repetoire of knowledge. Please continue posting. Frank

To: Sigmund who wrote (720)	12/19/1997 12:48:00 PM
From: Frank Buck	Read Replies (2) \| Respond to of 1894

Sigmund, Have you seen the latest release from AutoCyte? Here is an excerpt. "AutoCyte believes that recent market developments have caused the FDA to focus more attention on the performance of monolayer devices in analyzing high grade and cancerous lesions. These developments include the citizen petition filed with the FDA by a number of parties, including two cervical cytology companies - Cytology West and Trylon - to review the claims allowed for Cytyc's ThinPrep(TM) membrane-based monolayer process." biz.yahoo.com Do you have any knowledge of what the citizen petition filing is seeking and in what capacity the two cervical cytology companies are being used for? It appears as though Cytology West and Trylon are independently reassessing the merits of the claims of the ThinPrep system. I wonder what the citizen petition filing is all about? The statement by AutoCyte...."recent market developments have caused the FDA to focus more attention on the performance of monolayer devices in analyzing high grade and cancerous lesions" seems consistent with the medical-detection enhancing companies desires (like NPTH) to engage their systems to be compatible with the newest monolayer slide process. This is exactly the point I was referring to when I stated that NeoPath would be looked at in a "brighter" light because of the latest clearance by the FDA for the CYTC ThinPrep System. It now appears that AutoCyte is attempting to discredit the merits of the ThinPrep Slides efficacy and gain acceptance for their own system. The only thing that is a sure thing at this point is that the overall sector will be quagmired by the litigation for a while. Hopefully the dust will settle soon. Frank